KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Net Cash Flow (2016 - 2025)

AbbVie (ABBV) has disclosed Net Cash Flow for 14 consecutive years, with -$411.0 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 75.64% to -$411.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$337.0 million through Dec 2025, up 95.34% year-over-year, with the annual reading at -$337.0 million for FY2025, 95.34% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$411.0 million at AbbVie, up from -$830.0 million in the prior quarter.
  • The five-year high for Net Cash Flow was $5.3 billion in Q1 2024, with the low at -$5.9 billion in Q3 2024.
  • Average Net Cash Flow over 5 years is -$152.2 million, with a median of -$453.5 million recorded in 2023.
  • The sharpest move saw Net Cash Flow crashed 552.63% in 2021, then skyrocketed 311.01% in 2024.
  • Over 5 years, Net Cash Flow stood at -$2.4 billion in 2021, then decreased by 10.22% to -$2.7 billion in 2022, then soared by 81.31% to -$496.0 million in 2023, then crashed by 240.12% to -$1.7 billion in 2024, then soared by 75.64% to -$411.0 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$411.0 million, -$830.0 million, and $1.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.